Treatment of direct oral anticoagulants in patients with liver cirrhosis and portal vein thrombosis

키워드

참고문헌 (91)

1. Lisman T, "Pathogenesis, prevention, and management of bleeding and thrombosis in patients with liver diseases", Res Pract Thromb Haemost, 1, pp.150~161 (2017)
2. Ghazaleh S, "Efficacy and safety of anticoagulation in non-malignant portal vein thrombosis in patients with liver cirrhosis : a systematic review and meta-analysis", Ann Gastroenterol, 34, pp.104~110 (2021)
3. Tripodi A, "The coagulopathy of chronic liver disease", N Engl J Med, 365, pp.147~156 (2011)
4. Kovalic AJ, "Systematic review with meta-analysis : abnormalities in the international normalised ratio do not correlate with periprocedural bleeding events among patients with cirrhosis", Aliment Pharmacol Ther, 52, pp.1298~1310 (2020)
5. Drolz A, "Coagulation parameters and major bleeding in critically ill patients with cirrhosis", Hepatology, 64, pp.556~568 (2016)
6. Cholongitas E, "Risk factors, sequential organ failure assessment and model for end-stage liver disease scores for predicting short term mortality in cirrhotic patients admitted to intensive care unit", Aliment Pharmacol Ther, 23, pp.883~893 (2006)
7. Zheng K, "Risk of stroke in liver cirrhosis : a systematic review and meta-analysis", J Clin Gastroenterol, 54, pp.96~105 (2020)
8. Dabbagh O, "Coagulopathy does not protect against venous thromboembolism in hospitalized patients with chronic liver disease", Chest, 137, pp.1145~1149 (2010)
9. Aldawood A, "The incidence of venous thromboembolism and practice of deep venous thrombosis prophylaxis in hospitalized cirrhotic patients", Thromb J, 9, pp.1~ (2011)
10. Zanetto A, "Acute kidney injury in decompensated cirrhosis is associated with both hypo-coagulable and hyper-coagulable features", Hepatology, 72, pp.1327~1340 (2020)
11. Whiting D, "TEG and ROTEM : technology and clinical applications", Am J Hematol, 89, pp.228~232 (2014)
12. O’Leary JG, "AGA clinical practice update : coagulation in cirrhosis", Gastroenterology, 157, pp.34~43.e1 (2019)
13. Serag WM, "Predicting the risk of portal vein thrombosis in patients with liver cirrhosis and hepatocellular carcinoma", Heliyon, 6, pp.e04677~ (2020)
14. Stine JG, "Portal vein thrombosis, mortality and hepatic decompensation in patients with cirrhosis : a meta-analysis", World J Hepatol, 7, pp.2774~2780 (2015)
15. Gómez-Outes A, "Direct-acting oral anticoagulants : pharmacology, indications, management, and future perspectives", Eur J Haematol, 95, pp.389~404 (2015)
16. Weinberg EM, "Direct-acting oral anticoagulants(DOACs)in cirrhosis and cirrhosis-associated portal vein thrombosis", Semin Liver Dis, 39, pp.195~208 (2019)
17. European Association for the Study of the Liver, "EASL clinical practice guidelines : vascular diseases of the liver", J Hepatol, 64, pp.179~202 (2016)
18. DeLeve LD, "Vascular disorders of the liver", Hepatology, 49, pp.1729~1764 (2009)
19. Northup PG, "Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease : 2020 practice guidance by the American association for the study of liver diseases", Hepatology, 73, pp.366~413 (2021)
20. Harmanci O, "How can portal vein cavernous transformation cause chronic incomplete biliary obstruction?", World J Gastroenterol, 18, pp.3375~3378 (2012)
21. Young K, "Evaluation and management of acute and chronic portal vein thrombosis in patients with cirrhosis", Clin Liver Dis(Hoboken), 10, pp.152~156 (2018)
22. Senzolo M, "Current knowledge and management of portal vein thrombosis in cirrhosis", J Hepatol, 75, pp.442~453 (2021)
23. Zocco MA, "Thrombotic risk factors in patients with liver cirrhosis : correlation with MELD scoring system and portal vein thrombosis development", J Hepatol, 51, pp.682~689 (2009)
24. Stine JG, "Decreased portal vein velocity is predictive of the development of portal vein thrombosis : a matched case-control study", Liver Int, 38, pp.94~101 (2018)
25. Maruyama H, "De novo portal vein thrombosis in virus-related cirrhosis : predictive factors and long-term outcomes", Am J Gastroenterol, 108, pp.568~574 (2013)
26. Francoz C, "Portal vein thrombosis, cirrhosis, and liver transplantation", J Hepatol, 57, pp.203~212 (2012)
27. Tripodi A, "Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis", J Hepatol, 59, pp.265~270 (2013)
28. Violi F, "Patients with liver cirrhosis suffer from primary haemostatic defects? Fact or fiction?", J Hepatol, 55, pp.1415~1427 (2011)
29. Lisman T, "Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity", Hepatology, 44, pp.53~61 (2006)
30. Moore KL, "Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro", J Clin Invest, 79, pp.124~130 (1987)
31. de Franchis R, "Expanding consensus in portal hypertension: report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension", J Hepatol, 63, pp.743~752 (2015)
32. Sarin SK, "Toward a comprehensive new classification of portal vein thrombosis in patients with cirrhosis", Gastroenterology, 151, pp.574~577.e3 (2016)
33. Yerdel MA, "Portal vein thrombosis in adults undergoing liver transplantation : risk factors, screening, management, and outcome", Transplantation, 69, pp.1873~1881 (2000)
34. Ogren M, "Portal vein thrombosis : prevalence, patient characteristics and lifetime risk : a population study based on 23, 796 consecutive autopsies", World J Gastroenterol, 12, pp.2115~2119 (2006)
35. Noronha Ferreira C, "Anticoagulation in cirrhosis and portal vein thrombosis is safe and improves prognosis in advanced cirrhosis", Dig Dis Sci, 64, pp.2671~2683 (2019)
36. Violi F, "Incidence and recurrence of portal vein thrombosis in cirrhotic patients", Thromb Haemost, 119, pp.496~499 (2019)
37. Nery F, "Causes and consequences of portal vein thrombosis in 1, 243patients with cirrhosis : results of a longitudinal study", Hepatology, 61, pp.660~667 (2015)
38. Noronha Ferreira C, "Incidence, predictive factors and clinical significance of development of portal vein thrombosis in cirrhosis : a prospective study", Liver Int, 39, pp.1459~1467 (2019)
39. Abdel-Razik A, "De-novo portal vein thrombosis in liver cirrhosis : risk factors and correlation with the model for end-stage liver disease scoring system", Eur J Gastroenterol Hepatol, 27, pp.585~592 (2015)
40. Zhang Y, "Prevalence and clinical significance of portal vein thrombosis in patients with cirrhosis and acute decompensation", Clin Gastroenterol Hepatol, 18, pp.2564~2572.e1 (2020)
41. Mulloy B, "Pharmacology of heparin and related drugs", Pharmacol Rev, 68, pp.76~141 (2016)
42. Ansell J, "Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition)", Chest, 133(6 Suppl), pp.160s~198s (2008)
43. Ansell J, "The pharmacology and management of the vitamin K antagonists: the seventh ACCP conference on antithrombotic and thrombolytic therapy", Chest, 126(3 Suppl), pp.204s~233s (2004)
44. Hauel NH, "Structure-based design of novel potent nonpeptide thrombin inhibitors", J Med Chem, 45, pp.1757~1766 (2002)
45. Wienen W, "In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate", Thromb Haemost, 98, pp.155~162 (2007)
46. Garcia D, "The new oral anticoagulants", Blood, 115, pp.15~20 (2010)
47. Rugivarodom M, "Nontumoral portal vein thrombosis : a challenging consequence of liver cirrhosis", J Clin Transl Hepatol, 8, pp.432~444 (2020)
48. Loffredo L, "Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis : a systematic review and meta-analysis", Gastroenterology, 153, pp.480~487.e1 (2017)
49. Qi X, "Anticoagulation for the treatment of portal vein thrombosis in liver cirrhosis : a systematic review and meta-analysis of observational studies", Eur J Intern Med, 26, pp.23~29 (2015)
50. Delgado MG, "Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis", Clin Gastroenterol Hepatol, 10, pp.776~783 (2012)
51. Wang L, "Anticoagulation favors thrombus recanalization and survival in patients with liver cirrhosis and portal vein thrombosis : results of a meta-analysis", Adv Ther, 38, pp.495~520 (2021)
52. Loudin M, "Portal vein thrombosis in cirrhosis", J Clin Gastroenterol, 51, pp.579~585 (2017)
53. Dongmei Zhao, "Portal pressure gradient and serum albumin: A simple combined parameter associated with the appearance of ascites in decompensated cirrhosis treated with transjugular intrahepatic portosystemic shunt", Clinical and Molecular Hepatology, 25(2), pp.210~217 (2019), 대한간학회
54. Turon F, "Portal vein thrombosis : yes or no on anticoagulation therapy", Curr Opin Organ Transplant, 23, pp.250~256 (2018)
55. Riggio O, "Emerging issues in the use of transjugular intrahepatic portosystemic shunt(TIPS)for management of portal hypertension : time to update the guidelines?", Dig Liver Dis, 42, pp.462~467 (2010)
56. Hepatobiliary Disease Study Group, "Consensus for management of portal vein thrombosis in liver cirrhosis(2020, Shanghai)", J Dig Dis, 22, pp.176~186 (2021)
57. Rodrigues SG, "Systematic review with meta-analysis : portal vein recanalisation and transjugular intrahepatic portosystemic shunt for portal vein thrombosis", Aliment Pharmacol Ther, 49, pp.20~30 (2019)
58. Lv Y, "Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis : a randomised controlled trial", Gut, 67, pp.2156~2168 (2018)
59. Wang Z, "Is post-TIPS anticoagulation therapy necessary in patients with cirrhosis and portal vein thrombosis? A randomized controlled trial", Radiology, 279, pp.943~951 (2016)
60. Yue-Meng W, "Portal vein thrombosis in patients with cirrhosis undergoing elective transjugular intrahepatic portosystemic shunt : risk factors, warfarin efficacy, and clinical outcomes", Clin Appl Thromb Hemost, 24, pp.462~470 (2018)
61. Husted S, "Non-vitamin K antagonist oral anticoagulants(NOACs) : no longer new or novel", Thromb Haemost, 111, pp.781~782 (2014)
62. Schwarb H, "New direct oral anticoagulants(DOAC)and their use today", Dent J(Basel), 4, pp.5~ (2016)
63. Helms TM, "Consensus statement : management of oral anticoagulation for stroke prevention in patients with nonvalvular atrial fibrillation", Her zschrittmacherther Elektrophysiol, 27, pp.295~306 (2016)
64. Connolly SJ, "Dabigatran versus warfarin in patients with atrial fibrillation", N Engl J Med, 361, pp.1139~1151 (2009)
65. Patel MR, "Rivaroxaban versus warfarin in nonvalvular atrial fibrillation", N Engl J Med, 365, pp.883~891 (2011)
66. Granger CB, "Apixaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 365, pp.981~992 (2011)
67. Giugliano RP, "Edoxaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 369, pp.2093~2104 (2013)
68. Intagliata NM, "Direct oral anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation", Dig Dis Sci, 61, pp.1721~1727 (2016)
69. Hum J, "The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis", Eur J Haematol, 98, pp.393~397 (2017)
70. De Gottardi A, "Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis", Liver Int, 37, pp.694~699 (2017)
71. Nagaoki Y, "Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis", Hepatol Res, 48, pp.51~58 (2018)
72. Scheiner B, "Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function", Wien Klin Wochenschr, 130, pp.446~455 (2018)
73. Hanafy AS, "Randomized controlled trial of rivaroxaban versus warfarin in the management of acute nonneoplastic portal vein thrombosis", Vascul Pharmacol, 113, pp.86~91 (2019)
74. Lv Y, "Anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis : a prospective observational study", Am J Gastroenterol, 116, pp.1447~1464 (2021)
75. Ai MH, "Efficacy and safety study of direct-acting oral anticoagulants for the treatment of chronic portal vein thrombosis in patients with liver cirrhosis", Eur J Gastroenterol Hepatol, 32, pp.1395~1400 (2020)
76. Schulman S, "Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients", J Thromb Haemost, 3, pp.692~694 (2005)
77. Sasso R, "Anticoagulation therapy in patients with liver cirrhosis is associated with an increased risk of variceal hemorrhage", Am J Med, 132, pp.758~766 (2019)
78. Cosmas Rinaldi Adithya Lesmana, "Managing liver cirrhotic complications: Overview of esophageal and gastric varices", Clinical and Molecular Hepatology, 26(4), pp.444~460 (2020), 대한간학회
79. Jin Wook Chung, "Role of endoscopic treatment or balloon-occluded retrograde transvenous obliteration in patients with Child-Pugh class C end-stage liver cirrhosis and esophageal", gastric varices, 2019, pp.25(2), 181~182[DOI]
80. Keiji Yokoyama, "Endoscopic treatment or balloon-occluded retrograde transvenous obliteration is safe for patients with esophageal", gastric varices in Child-Pugh class C end-stage liver cirrhosis, 2019, pp.25(2), 183~189[DOI]
81. Mort JF, "Rates of bleeding and discontinuation of direct oral anticoagulants in patients with decompensated cirrhosis", Clin Gastroenterol Hepatol, 19, pp.1436~1442 (2021)
82. Elhosseiny S, "Direct oral anticoagulants in cirrhotic patients : current evidence and clinical observations", Can J Gastroenterol Hepatol, 2019, pp.4383269~ (2019)
83. Raymond J, "Pharmacogenetics of direct oral anticoagulants : a systematic review", J Pers Med, 11, pp.37~ (2021)
84. Graff J, "Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment", Clin Pharmacokinet, 52, pp.243~254 (2013)
85. Pollack CV Jr, "Idarucizumab for dabigatran reversal-full cohort analysis", N Engl J Med, 377, pp.431~441 (2017)
86. Kubitza D, "Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct factor Xa inhibitor", Br J Clin Pharmacol, 76, pp.89~98 (2013)
87. Byon W, "Apixaban : a clinical pharmacokinetic and pharmacodynamic review", Clin Pharmacokinet, 58, pp.1265~1279 (2019)
88. Mendell J, "An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics", J Clin Pharmacol, 55, pp.1395~1405 (2015)
89. Connolly SJ, "Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors", N Engl J Med, 380, pp.1326~1335 (2019)
90. Chen A, "Direct oral anticoagulant use : a practical guide to common clinical challenges", J Am Heart Assoc, 9, pp.e017559~ (2020)
91. Salmonson T, "Nonvitamin-K oral anticoagulants and laboratory testing: now and in the future: views from a workshop at the European Medicines Agency (EMA)", Eur Heart J Cardiovasc Pharmacother, 3, pp.42~47 (2017)

관련 논문AI추천